We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sugar Supplement Fuels the Failing Heart

By Biotechdaily staff writers
Posted on 03 Apr 2007
D-ribose, a simple, five-carbon sugar, has been shown to improve functional capacity, quality of life, and everyday activities for patients afflicted with congestive heart failure (CHF).
D-Ribose, unlike glucose, is a 5-carbon monosaccharide (pentose sugar) important for DNA, RNA, and most importantly, adenosine tri-phosphate (ATP), the energy currency of the cells. More...
ATP is crucial in maintaining the integrity and function of every cell, which is necessary for day-to-day health. By helping to replenish ATP supply, ribose increases cardiac energy reserves that become depressed during ischemia or hypoxia associated with coronary artery disease (CAD) or CHF by improving diastolic function.
Bioenergy Ribose is a dietary additive for energy enhancement. About 2-5 gm are generally adequate for added energy. To maximize athletic performance, assist CHF patients, or to keep energy pools high during strenuous activity, slightly larger doses may be required. Bioenergy Ribose, a product of Bioenergy Life Science (Minneapolis, MN, USA), is a mildly sweet, completely soluble food supplement. It mixes easily with juice, milk, or other cold foods.
"The number of heart failure patients continues to grow every year. By replenishing ATP to an energy-deficient heart we can significantly improve a patient's quality of life,” said John St. Cyr, M.D., Ph.D., medical director of Bioenergy Life Science. "We've learned recently that patients with heart disease may have a deficient supply of high energy compounds. Past studies have demonstrated that D-ribose supplementation enhances the return of ATP levels with an associated improvement in diastolic function.”

In the body, ribose is made from glucose (a simple six-carbon sugar) through a pathway called the pentose phosphate pathway (PPP) or hexose monophosphate shunt (HMS). The physiologically functional form of ribose, called 5-phosphoribosyl-1-pyrophosphate (PRPP), regulates the metabolic pathway that synthesizes energy compounds in all living tissue.



Related Links:
Bioenergy Life Science

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.